Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats

References

• Abidi P, Zhou Y, Jiang JD, Liu J. 2005. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 25(10):2170–2176. doi: 10.1161/01.ATV.0000181761.16341.2b.
   PubMed Web of Science ®Google Scholar
• Balasubramanian R, Maideen NMP. 2021. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab. 22(5):328–341.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Corsini A. 2018. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 17(1):25–37. doi: 10.1080/14740338.2018.1394455.
   PubMed Web of Science ®Google Scholar
• Benes LB, Bassi NS, Davidson MH. 2016. The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: does statin type matter? Prog Cardiovasc Dis. 59(2):145–152. doi: 10.1016/j.pcad.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. 2017. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 37(2):173–178. doi: 10.1111/liv.13308.
   PubMed Web of Science ®Google Scholar
• Cao S, Zhou Y, Xu P, Wang Y, Yan J, Bin W, Qiu F, Kang N. 2013. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells. J Ethnopharmacol. 149(2):576–582. doi: 10.1016/j.jep.2013.07.025.
   PubMed Web of Science ®Google Scholar
• Causevic-Ramosevac A, Semiz S. 2013. Drug interactions with statins. Acta Pharm. 63(3):277–293. doi: 10.2478/acph-2013-0022.
   PubMed Web of Science ®Google Scholar
• Chen C, Wu ZT, Ma LL, Ni X, Lin YF, Wang L, Chen KP, Huang CG, Pan G. 2015. Organic anion-transporting polypeptides contribute to the hepatic uptake of berberine. Xenobiotica. 45(12):1138–1146. doi: 10.3109/00498254.2015.1042537.
   PubMed Web of Science ®Google Scholar
• Cui M, Zhu F, Yin Y, Sui Y, Yan X, Chen T. 2022. Influence of gegenqinlian decoction on pharmacokinetics and pharmacodynamics of atorvastatin calcium in hyperlipidemic rats. Eur J Drug Metab Pharmacokinet. 47(1):117–126. doi: 10.1007/s13318-021-00738-5.
   PubMed Web of Science ®Google Scholar
• Dai LL, Fan L, Wu HZ, Tan ZR, Chen Y, Peng XD, Shen MX, Yang GP, Zhou HH. 2013. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects. Xenobiotica. 43(10):862–867. doi: 10.3109/00498254.2013.773385.
   PubMed Web of Science ®Google Scholar
• Devaraj NK, Mohamed M, Hussein N. 2017. Prevalence, factors influencing and knowledge about adherence to lipid-lowering therapy among hyperlipidemia patients. Med J Malaysia. 72(3):157–164.
   PubMedGoogle Scholar
• Fei X, Liu G. 2020. Influences of Gegen Qinlian decoction combined with atrovastatin on blood lipid level in elderly patients with coronary heart disease and hyperlipidemia. Chin J Integr Med Cardio Cerebrovasc Dis. 18(02):212–215.
   Google Scholar
• Feng P, Zhao L, Guo F, Zhang B, Fang L, Zhan G, Xu X, Fang Q, Liang Z, Li B. 2018. The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact. 293:115–123. doi: 10.1016/j.cbi.2018.07.022.
   PubMed Web of Science ®Google Scholar
• Feng PF, Zhu LX, Jie J, Yang PX, Chen X. 2021. The intracellular mechanism of berberine-induced inhibition of CYP3A4 activity. Curr Pharm Des. 27(40):4179–4185. doi: 10.2174/1381612827666210715155809.
   PubMed Web of Science ®Google Scholar
• Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, Barrea L, Hassan STS, Šmejkal K, Malaník M, et al. 2019. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics. 9(7):1923–1951. doi: 10.7150/thno.30787.
   PubMed Web of Science ®Google Scholar
• Guo CX, Pei Q, Yin JY, Peng XD, Zhou BT, Zhao YC, Wu LX, Meng XG, Wang G, Li Q, et al. 2012. Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica. 42(8):784–790. doi: 10.3109/00498254.2012.661100.
   PubMed Web of Science ®Google Scholar
• Hirota T, Fujita Y, Ieiri I. 2020. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 16(9):809–822. doi: 10.1080/17425255.2020.1801634.
   PubMed Web of Science ®Google Scholar
• Imenshahidi M, Hosseinzadeh H. 2019. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 33(3):504–523. doi: 10.1002/ptr.6252.
   PubMed Web of Science ®Google Scholar
• Jiri Mutu Z, Shilong L, Peng N, Yong’an L, Qinying AI, Xiaojun Y, Hongning L, Yanhua JI, Zhijun Z. 2022. Efficacy of Kushen decoction on high-fat-diet-induced hyperlipidemia in rats. J Tradit Chin Med. 42(3):364–371.
   PubMed Web of Science ®Google Scholar
• Karr S. 2017. Epidemiology and management of hyperlipidemia. Am J Manag Care. 23(9):S139–S148.
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 10(12):1344–1351. doi: 10.1038/nm1135.
   PubMed Web of Science ®Google Scholar
• Kumar A, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Ekavali 2015. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. 761:288–297. doi: 10.1016/j.ejphar.2015.05.068.
   PubMed Web of Science ®Google Scholar
• Lai M, Peng H, Wu X, Chen X, Wang B, Su X. 2022. IL-38 in modulating hyperlipidemia and its related cardiovascular diseases. Int Immunopharmacol. 108:108876. doi: 10.1016/j.intimp.2022.108876.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. 2011. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 39(10):1954–1960. doi: 10.1124/dmd.111.040592.
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Xie L, Gan D, Jiang X. 2016. Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. Pharm Biol. 54(12):2886–2894. doi: 10.1080/13880209.2016.1190762.
   PubMed Web of Science ®Google Scholar
• Liu Y, Pu QH, Wu MJ, Yu C. 2016. Proteomic analysis for the impact of hypercholesterolemia on expressions of hepatic drug transporters and metabolizing enzymes. Xenobiotica. 46(10):940–947. doi: 10.3109/00498254.2016.1144228.
   PubMed Web of Science ®Google Scholar
• McIver LA, Siddique MS. 2023. Atorvastatin. In: statPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430779/.
   Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. 2006. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 80(6):565–581. doi: 10.1016/j.clpt.2006.09.003.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC, Citarrella R, Montalto G, Rizzo M. 2020. An overview of statin-induced myopathy and perspectives for the future. Expert Opin Drug Saf. 19(5):601–615. doi: 10.1080/14740338.2020.1747431.
   PubMed Web of Science ®Google Scholar
• Paras C, Hussain MM, Rosenson RS. 2010. Emerging drugs for hyperlipidemia. Expert Opin Emerg Drugs. 15(3):433–451. doi: 10.1517/14728214.2010.481282.
   PubMed Web of Science ®Google Scholar
• Peng MF, Tian S, Song YG, Li CX, Miao MS, Ren Z, Li M. 2021. Effects of total flavonoids from Eucommia ulmoides Oliv. Leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. J Ethnopharmacol. 273:113947. doi: 10.1016/j.jep.2021.113947.
   PubMed Web of Science ®Google Scholar
• Qiu W, Jiang XH, Liu CX, Ju Y, Jin JX. 2009. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res. 23(11):1553–1558. doi: 10.1002/ptr.2808.
   PubMed Web of Science ®Google Scholar
• Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Emran TB, Mitra S, Khan Z, Alhumaydhi FA, Aljohani ASM, et al. 2021. Berberine as a potential anticancer agent: a comprehensive review. Molecules. 26(23):7368. doi: 10.3390/molecules26237368.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. Faseb J. 22(3):659–661. doi: 10.1096/fj.07-9574LSF.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Macchi C, Morlotti B, Sirtori CR, Magni P. 2014. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 25(5):401–406. doi: 10.1016/j.ejim.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Singh S, Zahoor I, Sharma N, Behl T, Kanojia N, Sehgal A, Mohan S, Almoshari Y, Salawi A, Aleya L, et al. 2022. Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia. Environ Sci Pollut Res Int. 29(51):76514–76531. doi: 10.1007/s11356-022-23043-3.
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. 2001. Statins: mechanism of action and effects. J Cell Mol Med. 5(4):378–387. doi: 10.1111/j.1582-4934.2001.tb00172.x.
   PubMed Web of Science ®Google Scholar
• Thakkar N, Slizgi JR, Brouwer KLR. 2017. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci. 106(9):2282–2294. doi: 10.1016/j.xphs.2017.04.053.
   PubMed Web of Science ®Google Scholar
• Voora D, Baye J, McDermaid A, Narayana Gowda S, Wilke RA, Nicole Myrmoe A, Hajek C, Larson EA. 2022. SLCO1B1*5 allele is associated with atorvastatin discontinuation and adverse muscle symptoms in the context of routine care. Clin Pharmacol Ther. 111(5):1075–1083. doi: 10.1002/cpt.2527.
   PubMed Web of Science ®Google Scholar
• Wang K, Feng X, Chai L, Cao S, Qiu F. 2017. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 49(2):139–157. doi: 10.1080/03602532.2017.1306544.
   PubMed Web of Science ®Google Scholar
• Wang L. 2022. Effect of atorvastatin combined with Ginkgo Biloba extract on cognitive function and serum uncoupling protein 2 and brain-derived neurotrophic factor levels in patients with intracranial artery stenosis. Chin Modern Med. 29(04):100–103.
   Google Scholar
• Wojcikowski K, Gobe G. 2014. Animal studies on medicinal herbs: predictability, dose conversion and potential value. Phytother Res. 28(1):22–27. doi: 10.1002/ptr.4966.
   PubMed Web of Science ®Google Scholar
• Wu N, Sarna LK, Siow YL, O K. 2011. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. Am J Physiol Regul Integr Comp Physiol. 300(3):R635–43. doi: 10.1152/ajpregu.00441.2010.
   PubMed Web of Science ®Google Scholar
• Wu X, Li Q, Xin H, Yu A, Zhong M. 2005. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 61(8):567–572. doi: 10.1007/s00228-005-0952-3.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Mao L, Zuo ML, Song GL, Tan LM, Yang ZB. 2022. The role of microRNAs in hyperlipidemia: from pathogenesis to therapeutical application. Mediators Inflamm. 2022:3101900–3101910. doi: 10.1155/2022/3101900.
   PubMed Web of Science ®Google Scholar
• Xie Y, He YB, Zhang SX, Pan AQ, Zhang J, Guan XH, Wang JX, Guo WS. 2014. Treatment of combined hyperlipidemia patients by jiangzhi tongluo soft capsule combined atorvastatin calcium tablet: a clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 34(9):1059–1063.
   PubMedGoogle Scholar
• Xu Y, Wu Y. 2020. Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: a case report and literature review. Medicine. 99(40):e22572. doi: 10.1097/MD.0000000000022572.
   PubMed Web of Science ®Google Scholar
• Yu RQ, Yuan JL, Ma LY, Qin QX, Wu XY. 2013. Probiotics improve obesity-associated dyslipidemia and insulin resistance in high-fat diet-fed rats. Zhongguo Dang Dai Er Ke Za Zhi. 15(12):1123–1127.
   PubMedGoogle Scholar
• Zechner J, Britza SM, Farrington R, Byard RW, Musgrave IF. 2022. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis. Life Sci. 291:119975. doi: 10.1016/j.lfs.2021.119975.
   PubMed Web of Science ®Google Scholar
• Zhang LS, Zhang JH, Feng R, Jin XY, Yang FW, Ji ZC, Zhao MY, Zhang MY, Zhang BL, Li XM. 2019. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med. 47(4):751–767. doi: 10.1142/S0192415X19500393.
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo J, Li J, Chen C, Su G. 2022. Pharmacokinetics and pharmacodynamic interaction of bergamottin with atorvastatin in rats. Xenobiotica. 52(5):463–467. doi: 10.1080/00498254.2022.2090301.
   PubMed Web of Science ®Google Scholar
• Zhang XB, Zeng LL, Liu Y, Xia SL. 2022. Curative effect of Gegen Qinlian decoction on damp-heat disease with angina pectoris and its influence on intestinal flora. Chinese J Clin Res. 35(12):1737–1740.
   Google Scholar
• Zhu F, Chen L, Zhu J. 2015. Influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke. Chinese J Contemp Neurol Neurosurg. 15(1): 43–47.
   Google Scholar